Podlesny, Blazej
Olszewska, Barbara
Yaari, Zvi
Jena, Prakrit V.
Ghahramani, Gregory
Feiner, Ron
Heller, Daniel A.
Janas, Dawid
Funding for this research was provided by:
Narodowe Centrum Nauki (2019/33/B/ST5/00631)
National Science Foundation (1752506)
National Cancer Institute, USA (R01-CA215719)
Cancer Center Support (P30 CA008748)
National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK114321)
Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University (UL1-TR002384)
American Cancer Society (GC230452)
Pershing Square Sohn Cancer Research Alliance
Honorable Tina Brozman Foundation
Polish-U.S. Fulbright Commission (PL/2019/67/STEM)
Politechnika Śląska (04/020/RGJ21/1016)
Article History
Received: 3 March 2021
Accepted: 4 May 2021
First Online: 19 May 2021
Competing interests
: D.A.H. is a cofounder and officer with equity interest of Goldilocks Therapeutics Inc., LipidSense Inc., and Nirova BioSense Inc. D.A.H. is a member of the scientific advisory boards of Concarlo Holdings LLC Nanorobotics Inc., and Mediphage Bioceuticals Inc. All other authors declare no competing interests.